UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 5, 2020

MICROVISION, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) **001-34170** (Commission File Number)

91-1600822 (I.R.S. Employer Identification Number)

6244 185th Avenue NE, Suite 100 Redmond, Washington 98052

(Address of Principal Executive Offices) (Zip Code)

(425) 936-6847

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

ſ

[]

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, \$0.001 par value per share	MVIS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company []

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Item 2.02. Results of Operations and Financial Condition.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

On August 5, 2020, MicroVision, Inc. issued a press release announcing its Second Quarter 2020 results. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1 MicroVision, Inc. Press Release Announces Second Quarter 2020 Results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MICROVISION, INC.

Date: August 5, 2020

By: <u>/s/ David J. Westgor</u> David J. Westgor Vice President, General Counsel & Secretary

MicroVision Announces Second Quarter 2020 Results

REDMOND, Wash., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display and sensing technology, today announced its second quarter 2020 results.

Revenue for the second quarter of 2020 was \$0.6 million, compared to \$1.2 million for the second quarter of 2019. MicroVision's net loss for the second quarter of 2020 was \$2.3 million, or \$0.02 per share, compared to a net loss of \$9.0 million, or \$0.08 per share for the second quarter of 2019. The Company ended the second quarter of 2020 with \$7.8 million in cash and cash equivalents, compared to \$5.8 million at the end of the fourth quarter of 2019.

"With the assistance of our financial advisor, Craig-Hallum Capital Group LLC, we continue to explore strategic alternatives to maximize the value of MicroVision for our shareholders, including the sale of a product vertical, strategic investment, or potential sale or merger of the Company," said Sumit Sharma, MicroVision's Chief Executive Officer.

Financial Results Webcast

MicroVision will host a webcast which will start at 2:00 p.m. Pacific Time on Wednesday, August 5, 2020 to discuss its second quarter results. Interested parties can listen to the company's webcast by accessing the Investor Relations section of MicroVision's website on the Investor Relations Events Calendar page at https://microvision.gcs-web.com/investor-event-calendar. Investors may submit questions for management in advance to IR@MicroVision.com or beginning 10 minutes before or during the live webcast on August 5, 2020. The webcast will be available for rebroadcast from the Investor Relations section of MicroVision's website on the Investor Relations Events Calendar page.

About MicroVision

MicroVision is the creator of PicoP® scanning technology, an ultra-miniature sensing and projection solution based on the laser beam scanning methodology pioneered by the Company. MicroVision's platform approach for this sensing and display solution means that its technology can be adapted to a wide array of applications and form factors. We combine our hardware, software, and algorithms to unlock value for our customers by providing them a differentiated advanced solution for a rapidly evolving, always-on world.

MicroVision has a substantial portfolio of patents relating to laser beam scanning projection and sensing. MicroVision's industry leading technology is a result of its extensive research and development. The Company is based in Redmond, Washington.

MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements

Certain statements contained in this release, including those relating to strategic alternatives, sale or merger of the Company, completing a transaction, the Company's future products and product applications and those including words like "explore" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the risk that the Company may not succeed in finding licensing or other strategic solutions, including a potential sale of the Company, with acceptable timing, benefits or costs, our ability to operate with limited cash or to raise additional capital when needed; market acceptance of our technologies and products; and for products incorporating our technologies; the failure of our commercial partners to perform as expected under our agreements, including from the impact of the COVID-19 (coronavirus); our ability to identify parties interested in paying any amounts or amounts we deem desirable for the purchase or license of intellectual property assets; our or our customers' failure to perform under open purchase orders, our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; our ability to maintain our listing on the Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect us to a greater extent than indicated. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

> MicroVision, Inc. Balance Sheet (In thousands) (Unaudited)

June 30,	December 31,
2020	2019

Assets

Current Assets				
Cash and cash equivalents	\$	7,805	\$	5,837
Accounts receivable, net		-		1,079
Inventory		-		192
Other current assets		301		729
Total current assets		8,106		7,837
Property and equipment, net		1,623		1,849
Operating lease right-of-use asset		1,132		1,308
Restricted cash		435		435
Intangible assets, net		192		221
Other assets		18		186
Total assets	<u>\$</u>	11,506	\$	11,836
Liabilities and Shareholders' Equity (Deficit)				
Current Liabilities				
Accounts payable	\$	1,498	\$	1,871
Accrued liabilities		501		2,045
Deferred revenue		-		21
Contract liabilities		8,699		9,755
Other current liabilities		-		83
Current portion of long-term debt		694		-
Current portion of operating lease liability	666			656
Current portion of finance lease obligations		20		25
Total current liabilities		12,078		14,456
Long term debt, net of current portion		880		-
Operating lease liability, net of current portion	1,069			1,348
Finance lease obligations, net of current portion	1			9
Total liabilities		14,028		15,813
Commitments and contingencies				
Shareholders' Equity (Deficit)				
Common stock at par value		143		126
Additional paid-in capital		577,172		568,496
Accumulated deficit		(579,837)		(572,599)
Total shareholders' equity (deficit)		(2,522)		(3,977)
Total liabilities and shareholders' equity (deficit)	\$	11,506	\$	11,836

MicroVision, Inc. **Statement of Operations** (In thousands, except earnings per share data) (Unaudited)

	Three months 2020		s ended June 30, 2019		Six months en 2020		nded June 30, 2019	
Product revenue	\$	-	\$	-	\$	· · ·	\$	199
License and royalty revenue		572 15		1,240		784 25		2,892
Total revenue		587		1,240	·	2,056		3,091
Cost of product revenue		(1)		1,025		1,394		1,313

Cost of contract revenue Total cost of revenue	(1)	798 1,823	4	1,753	
Gross margin	588	(583)	658	2	5
Research and development expense Sales, marketing, general and administrative expense Gain on disposal of fixed assets Total operating expenses	1,607 1,280 	5,945 2,455 	5,290 3,051 (450) 7,891	11,918 5,154 	4
Loss from operations	(2,299)	(8,983)	(7,233)	(17,047	7)
Other expense, net	(5)	(7)	(5)	(1)	1)
Net loss	\$ (2,304)	\$ (8,990)	\$ (7,238)	\$ (17,058	8)
Net loss per share - basic and diluted	\$ (0.02)	\$ (0.08)	\$ (0.05)	\$ (0.10	6)
Weighted-average shares outstanding - basic and diluted	140,107	106,872	133,661	104,435	5

Investor Relations Contact

David H. Allen Darrow Associates, Inc. 408.427.4463 dallen@darrowir.com